Corvus Pharmaceuticals
CRVS
38 hedge funds and large institutions have $69M invested in Corvus Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 7 closing their positions.
1,469% more call options, than puts
Call options by funds: $204K | Put options by funds: $13K
24% more capital invested
Capital invested by funds: $55.6M → $69M (+$13.4M)
0% more funds holding
Funds holding: 38 → 38 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
11.73% less ownership
Funds ownership: 73.14% → 61.4% (-12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$875K |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$586K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$216K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$200K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$6.15M |
| 2 |
Millennium Management
New York
|
-$3.24M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.01M |
| 4 |
Renaissance Technologies
New York
|
-$627K |
| 5 |
BlackRock
New York
|
-$595K |
CRVS Hedge Fund Activity: Q3 2020 in Review
38 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2020, worth a combined $69M — up 24% from $55.6M a quarter earlier.
Fund positioning in CRVS was balanced in Q3 2020: 7 funds opened new positions, 7 closed out, 11 added to existing stakes and 12 trimmed.
The largest buyer was CHI Advisors, adding an estimated $875K. The largest seller was Novo Holdings A/S, cutting an estimated $6.15M.
- 38 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $69M of Corvus Pharmaceuticals stock for Q3 2020, up 24% quarter-over-quarter.
- 7 funds opened new Corvus Pharmaceuticals positions in Q3 2020 and 7 closed out, a net change of 0 holders.
- The largest Corvus Pharmaceuticals buyer in Q3 2020 was CHI Advisors, an estimated $875K added.
- The largest Corvus Pharmaceuticals seller in Q3 2020 was Novo Holdings A/S, an estimated $6.15M sold.
Based on aggregated 13F filings for Q3 2020.